ConductScience.org, home

Comparison · NCT00235495-ceecb985

Albumin vs Saline: The Number of Participants With a Score on the mRS of 0-2 at 90 Days.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Albumin vs Saline: The Number of Participants With a Score on the mRS of 0-2 at 90 Days. Trial comparisons, record NCT00235495-ceecb985. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00235495-ceecb985

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5380.490.585wilson
Risk in group 20.5270.480.575wilson
Risk difference, group 1 minus group 20.0105-0.05670.0775newcombe hybrid score
Risk ratio, group 1 over group 21.020.8991.16log
Odds ratio, group 1 over group 21.040.7951.37log
Number needed to treat, for one more participant with the outcome on Albumin than on Saline95.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AlbuminTreatment with 25% Albumin, 2.0 g/kg227422OG000
Group 2SalineTreatment with same volume of normal saline221419OG001

Outcome

Type
SECONDARY
Title
The Number of Participants With a Score on the mRS of 0-2 at 90 Days.
Description
The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.
Time frame
at 90 days
Population
Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.

Source ClinicalTrials.gov

Trial

Title
Albumin in Acute Ischemic Stroke Trial
NCT number
NCT00235495
Phases
PHASE3
Conditions
Ischemic Stroke
Interventions
Albumin, Saline
Lead sponsor
University of Miami
Results first posted
2019-09-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00235495-ceecb985